Vident Advisory LLC Acquires Shares of 8,684 DaVita Inc. $DVA

Key Points

• Vident Advisory LLC has invested approximately $1.33 million in DaVita Inc. by acquiring 8,684 shares, marking a new position for the advisory firm in the company's stock.
• DaVita reported earnings of $2.95 per share for the last quarter, exceeding expectations of $2.70, and achieved a year-over-year revenue increase of 6.1% to $3.38 billion.
• Institutional investors currently own 90.12% of DaVita's stock, reflecting significant confidence from large financial stakeholders in the company.

Vident Advisory LLC acquired a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 8,684 shares of the company's stock, valued at approximately $1,328,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. UMB Bank n.a. boosted its position in DaVita by 65.5% during the first quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after purchasing an additional 76 shares in the last quarter. National Pension Service lifted its position in shares of DaVita by 74.3% in the first quarter. National Pension Service now owns 197 shares of the company's stock valued at $30,000 after acquiring an additional 84 shares in the last quarter. Copia Wealth Management purchased a new stake in shares of DaVita in the fourth quarter valued at $30,000. Y.D. More Investments Ltd purchased a new stake in shares of DaVita in the first quarter valued at $35,000. Finally, University of Texas Texas AM Investment Management Co. purchased a new position in DaVita during the first quarter worth about $83,000. Institutional investors and hedge funds own 90.12% of the company's stock.

Insider Activity

In other news, insider James O. Hearty sold 2,351 shares of the stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the sale, the insider owned 26,038 shares in the company, valued at approximately $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.50% of the company's stock.

DaVita Stock Up 1.6%

Shares of DVA stock traded up $2.16 during trading hours on Friday, reaching $137.72. The company had a trading volume of 659,996 shares, compared to its average volume of 686,564. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39. DaVita Inc. has a twelve month low of $126.07 and a twelve month high of $179.60. The company has a market capitalization of $9.85 billion, a P/E ratio of 13.54, a price-to-earnings-growth ratio of 0.99 and a beta of 1.13. The stock's fifty day simple moving average is $139.40 and its 200 day simple moving average is $141.85.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The business had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.36 billion. During the same quarter last year, the firm earned $2.00 earnings per share. The company's revenue for the quarter was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on DVA shares. Truist Financial set a $148.00 target price on DaVita in a research report on Friday, August 8th. Barclays dropped their price target on DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th. Finally, Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research note on Friday, August 22nd. Three research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $164.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.